Quality of life

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Retrieved on: 
Wednesday, September 28, 2022
Hospital, Degenerative disease, Inflammation, Safety, CRDL, TSX, COVID-19, Pericardium, Fibrosis, Nursing, FDA, Heart Failure Society of America, Biomarker, IND, Myocarditis, Company, Poster, Secondary research, News, Heart failure, Therapy, Patient, Risk, History, Physician, Quality of life, Pharmacist, Cardiovascular disease, Practitioner, NASDAQ, Cannabidiol, ARCHER, Research, CVD, Fatigue, Education, Death, Pharmaceutical industry

The poster will be presented for general viewing within the "Basic and Translational Science" category of the HFSA2022 Scientific Programme on September 30, 2022, from 6:15 6:30 PM EDT.

Key Points: 
  • The poster will be presented for general viewing within the "Basic and Translational Science" category of the HFSA2022 Scientific Programme on September 30, 2022, from 6:15 6:30 PM EDT.
  • The Heart Failure Society of America is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy.
  • The Company's lead product candidate, CardiolRx, is an oral pharmaceutical that is being clinically developed for use in CVD.
  • In addition, CardiolRx is being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the "LANCER" trial).

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Retrieved on: 
Wednesday, September 28, 2022
Odyssey, Safety, Volunteering, Common, Woman, SRC, Risk, Brain, FDA, Food, Chronic traumatic encephalopathy, EKG, Phase, Blood, Army, Falls, Concussion, Intellectual property, CTE, Clinical trial, OTC, Vital signs, Quality of life, SAD, MAD, Patient safety, United States Army Medical Command, GLOBE, Food and Drug Administration, Lists of diseases, Pharmaceutical industry

Odysseys trial involved administering PRV-002, the Companys novel drug to treat concussion, to healthy human subjects.

Key Points: 
  • Odysseys trial involved administering PRV-002, the Companys novel drug to treat concussion, to healthy human subjects.
  • The Phase I trial was conducted at Avance Clinical and Nucleus Network, two leading clinical research organizations.
  • Odyssey is currently communicating with the Food and Drug Administration (FDA) to present the findings from the Phase I Trial.
  • Phase II trial sites are being identified and study design is being created with the sites medical leadership and Odyssey Medical Advisors.

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

Retrieved on: 
Wednesday, September 28, 2022
Radiology, Health, FIU Herbert Wertheim College of Medicine, Securities Exchange Act of 1934, Safety, COVID-19, FDA, Drug Quality and Security Act, CIO, Pancreatic cancer, Neoplasm, Nature, Intellectual property, Securities Act of 1933, Industry, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Survival, Interventional radiology, FSVM, Cancer, Technology, Blood, Quality of life, Standard of care, Cholangiocarcinoma, Terminology, Nasdaq, Loews Hotels, Founder, Florida International University, Research, Security (finance), Pharmaceutical industry, Medical imaging, LAPC

Since 2018, Dr. Gandhi has been instrumental in the multi-center Phase 3 TIGeR-PaC clinical trial as a principal investigator for the Miami Cancer Institute.

Key Points: 
  • Since 2018, Dr. Gandhi has been instrumental in the multi-center Phase 3 TIGeR-PaC clinical trial as a principal investigator for the Miami Cancer Institute.
  • Dr. Gandhis presentation, Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer, provides an overview of the clinical challenges of the standard-of-care treatment, available to locally advanced pancreatic cancer (LAPC) patients.
  • It may be ineffective in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy.
  • RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

Bayer Fund Announces $8.2M in Donations to U.S. Nonprofit Organizations During First Half of 2022

Retrieved on: 
Wednesday, September 28, 2022
Pharmaceutical, Training, Education, Oncology, Philanthropy, Fitness & Nutrition, Fund Raising, Cardiology, Foundation, Family, Science, Other Philanthropy, Other Science, Consumer, Health, Medical Supplies, Oakland Unified School District, Fund, Chabot Space and Science Center, Nutrition, Health, Communication, Student, Science, technology, engineering, and mathematics, Organization, Learning, Computer science and engineering, Program, Pregnancy, Patient, Mental health, Cancer, Wellness, STEM, Â, Quality of life, Solution, Yoga, CA, Guangdong-Hong Kong-Macau Greater Bay Area, Alternative medicine, Cardiovascular disease, Awareness, Education, OFS, Pharmaceutical industry, Tutoring, Science, Engineering, Food, Bayer, Hunger, Mathematics, Technology

Bayer Fund, the philanthropic arm of Bayer in the U.S., is proud to announce today that it has provided a total of $8.2M in grant funding, spanning across 2,085 organizations, in the first half of 2022.

Key Points: 
  • Bayer Fund, the philanthropic arm of Bayer in the U.S., is proud to announce today that it has provided a total of $8.2M in grant funding, spanning across 2,085 organizations, in the first half of 2022.
  • Bayer Fund supports high-quality food and nutrition programs that aim to ensure access to healthy and nutritious foods.
  • Bayer Fund deeply understands the complex work we do, says Jocelyn Fundoukos, Director of Communications at OFS.
  • In 2021, Bayer Fund awarded more than $13.1 million to over 3,400 charitable and nonprofit organizations to help address essential needs in Food and Nutrition, STEM Education and Health & Wellness.

Fiber Broadband Association Publishes Supply Chain Mitigation Strategies for The Broadband Industry

Retrieved on: 
Wednesday, September 28, 2022
Telecommunications, Networks, Internet, Publishing, Hardware, Communications, Technology, Mobile, Wireless, Electronics, FBA, COVID-19, Policy, Association, Organization, Industry, Graybar, Supply, CEO, Technology, Quality of life, Ecosystem, MEA, Current, Vital statistics, APAC, Renewable energy, Internet service provider, LATAM

The Fiber Broadband Association (FBA) today announced it published the Strategies to Mitigate Bottlenecks in the Current Fiber Broadband Supply Chain white paper .

Key Points: 
  • The Fiber Broadband Association (FBA) today announced it published the Strategies to Mitigate Bottlenecks in the Current Fiber Broadband Supply Chain white paper .
  • Vital statistics are presented regarding the ongoing supply chain changes in the fiber broadband industry and examples of how to protect fiber-related projects from the negative effects of supply chain stressors.
  • The 24-page white paper was created by the Fiber Broadband Associations Supply Chain Working Group to examine how supply chain delays are crippling the fiber broadband ecosystem and provides various mitigation strategies to successfully and efficiently deploy new fiber networks.
  • The Fiber Broadband Association represents the full fiber industry ecosystem, and we pooled the collective experience and insights of our stakeholders to develop this very important white paper for the industry, said Scott Jackson, National Broadband Market Manager at Graybar, Fiber Broadband Association Board Member and Chair of the Supply Chain Working Group.

HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

Retrieved on: 
Wednesday, September 28, 2022
Health, Medical Devices, Technology, Other Technology, Software, General Health, Cardiology, Risk, Chest pain, FDA, Food, Coronavirus Scientific Advisory Board (Turkey), Arrhythmia, Review, Coronary artery disease, Forward-looking statement, No, MS, Patient, Analysis, CEO, Technology, United States Patent and Trademark Office, Quality of life, Financial condition report, Result, Patent, ECG, Diagnosis, Doctor of Philosophy, Atrial fibrillation, NASDAQ, Harvard Medical School, Myocardial infarction, Research, US Foods, Marketing, SEC, Medical device, MD

In contrast, the market for atrial fibrillation, the most targeted condition for detection by single-lead ECG technologies, is several times smaller.

Key Points: 
  • In contrast, the market for atrial fibrillation, the most targeted condition for detection by single-lead ECG technologies, is several times smaller.
  • A 12-lead ECG is the standard of care for detecting any cardiac condition and is considered one of the essential tools for heart attack detection.
  • No single lead ECG product currently in the marketplace is able to help diagnose a heart attack.
  • Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care.

Ananta Medicare Is Facilitating Endless Care for Everyone

Retrieved on: 
Wednesday, September 28, 2022
Health, Marketing, Quality of life, Cosmetics, Philosophy, Plant, Herbal, Medicare, Dietary supplement

FORT LAUDERDALE, Fla., Sept. 28, 2022 /PRNewswire/ -- Maintaining health (both on an individual and collective level) is an ongoing process. It requires proactive research, fostering the right habits, and finding the right health and wellness tools to maximize a healthy lifestyle. Cultivating sustainable health is an ongoing effort that the team at Ananta Medicare takes seriously — to the point where it's become an embedded philosophy within their corporate structure.

Key Points: 
  • Cultivating sustainable health is an ongoing effort that the team at Ananta Medicare takes seriously to the point where it's become an embedded philosophy within their corporate structure.
  • That's why our motto is to provide 'endless care about your health.'
  • Its innovative formulas are made to address the health needs of a large variety of audiences, with the objective of fostering an endless cycle of care for everyone.
  • About Ananta Medicare: Ananta Medicare Limited was founded in 1999 and consists of a group of companies that specialize in the manufacturing and marketing of high-quality products with natural components.

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Retrieved on: 
Wednesday, September 28, 2022
Pivotal, Securities Exchange Act of 1934, Lymph, Peripheral T-cell lymphoma, Woman, MF, PTCL, Biologics license application, FDA, COVID-19, Food, Drug Quality and Security Act, Malignancy, CGMP, NHL, Company, T-cell lymphoma, Hemorrhoid, Haematopoietic system, Securities Act of 1933, SS, Protein, Immunotherapy, Forward-looking statement, Patient, File, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, U.S. Securities and Exchange Commission, CEO, Pain, Quality of life, Regulation, Annual report, Interleukin, Fast Track, IL-2R, Cutaneous lymphoma, Research, BLA, SEC, Man, Immune system, ODD, Patent, Diphtheria, Mycosis fungoides, Disease, Itch, Pharmaceutical industry, Vaccine, CTCL, Citius, Altius, Fortius

"The treatment of advanced cutaneous T-cell lymphoma remains a complex and challenging unmet medical need.

Key Points: 
  • "The treatment of advanced cutaneous T-cell lymphoma remains a complex and challenging unmet medical need.
  • Each year, thousands of patients are diagnosed with CTCL, a debilitating orphan disease with no single standard of care.
  • "The BLA filing for denileukin diftitox marks the first of our pipeline candidates to be submitted for FDA approval."
  • I/ONTAK, a purified version of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK.

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis

Retrieved on: 
Wednesday, September 28, 2022
People, Janus, Adult, American Academy, EASI, Inflammation, Ocular rosacea, Safety, Awareness, Immunology, National Institute of Infectious Diseases, AD, Atopic dermatitis, Itchy, Conjunctivitis, Infection, Patient, Clinical trial, Immune-mediated inflammatory diseases, Forearm, Bleeding, Emotional well-being, Quality of life, American Academy of Dermatology, Eczema Area and Severity Index, JAK, Anxiety, Sleep, Briony Behets, Association, Overalls, PALO, BID, Skin, Asthma, HIV disease progression rates, Immune system, Depression, National Institute, Pharmaceutical industry, Vaccine, Silk, IRAK4, Dermatitis, Dermatology

The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.

Key Points: 
  • The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.
  • The Phase 2a study follows the successful completion of a Phase 1 healthy volunteer study which evaluated 18 adult patients with EVO101 0.1% topical cream, applied twice daily to the ventral aspect of one forearm for seven days.
  • In the Phase 2a study, AD patients will apply EVO101 cream twice daily for eight weeks.
  • "From inception, we have remained focused on rapidly progressing multiple candidates into proof-of-concept clinical studies," said Luis Pea, President and Chief Executive Officer of Evommune.

ReWalk Takes Another Step Toward Medicare Coverage

Retrieved on: 
Wednesday, September 28, 2022
Risk, Health, Time, Macs, Medicare, SCI, CMS, Company, Form 10-K, Stroke, Patient, Mental health, Phrase, CEO, Quality of life, Uncertainty, GLOBE, SEC, Annual report, Robotics, Health insurance, ReWalk

ReWalk Robotics is actively engaged with CMS in its commitment to evaluate complex advanced technologies like exoskeletons.

Key Points: 
  • ReWalk Robotics is actively engaged with CMS in its commitment to evaluate complex advanced technologies like exoskeletons.
  • In light of this announcement, ReWalk will begin submitting cases for Medicare beneficiaries with spinal cord injury (SCI) to the MACs.
  • This is the latest step in ReWalks efforts to expand access to the Companys exoskeletons for Medicare beneficiaries with SCI.
  • For more information on the ReWalk systems, please visit rewalk.com
    ReWalk and ReStore are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions.